As we recently reported that rafoxanide exerted ERS-dependent selective anti-tumor activity against CRC cells in vitro and in vivo [21], we first assessed whether treatment of CRC cells with increasing doses of rafoxanide—1.25, 2.5, and 5 μM, chosen accordingly with the aforementioned report, resulted in eIF2α phosphorylation. The gene discussed is EIF2A; the disease is colorectal carcinoma.